Partner Headlines - CPHD

  1. Rayno 2016 Life Science Portfolio Update

    TalkMarkets
  2. Biotech ETFs Lead Q3 Rally: XBI Breaks Out

    TalkMarkets
  3. Baron Funds Comments on Cepheid

    GuruFocus
  4. Columbia Wanger Ups Stake in Fiesta Restaurant

    GuruFocus
  5. Cepheid Announces Diagnostic Collaboration With MedImmune And ...

    Benzinga
  6. Take Profits Judiciously When You're Short A Stock

    IBD
  7. Benzinga's Top Upgrades

    Benzinga
  8. FIND And Cepheid Announce A Strategic Collaboration To Advance ...

    Benzinga
  9. Benzinga's Top Downgrades

    Benzinga
  10. Mid-Morning Market Update: Markets Mostly Flat; General Motors ...

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Mid-Afternoon Market Update: Colfax Drops On Weak Results; SanDisk ...

    Benzinga
  13. Mid-Day Market Update: Dow Drops Over 100 Points; TripAdvisor ...

    Benzinga
  14. Mid-Morning Market Update: Markets Gain; Bank of America Earnings ...

    Benzinga
  15. Morning Market Losers

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Tuesday's After-Hours Movers Led By SanDisk, Cepheid, JPMorgan ...

    Benzinga
  18. Stocks Fall For Fourth Day On Global Growth Worries

    IBD
  19. Major Indexes Extend Losses; Sucampo Bucks Weakness

    IBD
  20. Morning Market Losers

    Benzinga
  21. Stocks On Pace For Fourth Straight Gain; GoPro Gains

    IBD
  22. Stocks Hold On To Most Gains; Biotechs Quicken Their Pulse

    IBD
  23. Stocks Lower In Late Trading, But Utilities Rally

    IBD
  24. Craig-Hallum Upgrades Cepheid To Buy

    Benzinga
  25. Morning Market Gainers

    Benzinga
  26. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  27. Novartis, Verastem & Cepheid Making Biotech Headlines On Friday

    Benzinga
  28. Leading Medical Stock Cepheid Trying To Break Out

    IBD
  29. Benzinga's Top Upgrades

    Benzinga
  30. Bank of America Upgrades Cepheid To Buy

    Benzinga
  31. UPDATE: Citigroup Reiterates On Cepheid Following Positive Data

    Benzinga
  32. Top Medical Stocks: Cepheid Diagnostics Sales Strong

    IBD
  33. Cepheid Receives FDA Clearance For Xpert Norovirus, The First ...

    Benzinga
  34. CEPHEID

    IBD
  35. Cepheid Receives FDA Clearance For Xpert Flu/RSV XC

    Benzinga
  36. Cepheid To Develop Xpert Ebola For Countries Worst Hit By Epidemic

    Benzinga
  37. Several Sectors Emerge As Leaders Of New Market Uptrend

    IBD
  38. Stocks Fight Back To Finish Mixed

    IBD
  39. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD
  40. Cepheid Explores Test For Ebola Disease; Q3 Beats

    IBD
  41. CEPHEID

    IBD
  42. Cepheid Extends Reach Of Direct US Commercial Operations

    Benzinga
  43. UPDATE: ISI Group Upgrades Cepheid

    Benzinga
  44. CEPHEID

    IBD
  45. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  46. Alexion Takes Off On Outlook

    IBD
  47. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  48. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  49. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  50. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  51. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  52. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  53. Benzinga's Top Downgrades

    Benzinga
  54. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  55. Benzinga's Top Downgrades

    Benzinga
  56. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  57. Cepheid Announces Board of Directors Changes

    Benzinga
  58. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  59. Medtech Stocks Moving As Conference Makes Waves

    IBD
  60. Medtech Stocks Moving As Conference Makes Waves

    IBD
  61. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  62. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  63. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  64. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  65. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  66. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  67. Stocks To Watch For December 28, 2012

    Benzinga
  68. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  69. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  70. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  71. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  72. Benzinga's Top Downgrades

    Benzinga
  73. Benzinga's Top Upgrades

    Benzinga
  74. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  75. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  76. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  77. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  78. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  79. Benzinga Mid-Afternoon Market Update

    Benzinga
  80. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  81. Benzinga Mid-Day Market Update

    Benzinga
  82. Mid-Morning Market Update

    Benzinga
  83. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  84. Benzinga's Top Initiations

    Benzinga
  85. A Peek Into The Market Before The Trading Starts

    Benzinga
  86. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  87. Benzinga's Top Initiations

    Benzinga
  88. Technology Sector Wrap

    FoxBusiness
  89. Technology Sector Wrap

    FoxBusiness
  90. Technology Sector Wrap

    FoxBusiness
  91. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  92. Cepheid Down 20% on Weak Guidance

    Benzinga
  93. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  94. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  95. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  96. A Peek Into The Market Before The Trading Starts

    Benzinga
  97. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  98. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  99. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  100. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
Trading Center